An essential ingredient for its final drug products used to
treat type II diabetes. Its action mechanism is binding to
sulfonylurea receptors on pancreatic beta cells, which is a
key step in its glucose-lowering effect. It was developed
by a Japanese pharma company and approved by there
government in 2004.

An indispensable component for FDA approved aromatic
allylic alcohol drugs used for the treatment of convulsion
concerned with Dravet syndrome, also used as combined
with other anticonvulsant. The research also has proven it
effective in inhibiting the growth of cancer cells.

It is a key component for the finidshed esmolol drugs used
for the short-term control of ventricular rate and heart
rate in different types of tachycardia, including
perioperative tachycardia and hypertension. It functions
by increasing of atrioventricular refractory time and
decreasing of oxygen demand of the myocardium.

We are a licensed APIs manufacturer under the trademark
Cysolvia® and committed to producing the top-quality
strontium ranelate product, a vital element for its final
drugs used to treat osteoporosis especially for
postmenopausal women. It has been approved in multiple
countries.

A GMP standard APIs manufacturer devoted to producing
the best quality delafloxacin meglumine for its final drugs
used for the treatment of acute bacterial skin and skin
structure infection caused by sensitive organism. We stress
the branding reputation and its values brought to
our customers.